Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.

The inspection concluded with the issuance of a Form 483 containing five observations. The company said it will respond to the US FDA within the stipulated timeline.

A Form 483 indicates procedural or compliance deficiencies noted during inspection and does not constitute a warning letter or import action at this stage.

Ajanta Pharma is primarily involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages.

The companys consolidated net profit jumped 17.6% to Rs 273.77 crore on 20% rise in revenue from operations to Rs 1,374.84 crore in Q3 FY26 over Q3 FY25.

Related Posts

ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

New Delhi: The Indian Council of Medical Research (ICMR) participated in the national programme ‘विज्ञान–Tech’, organised on the occasion of National Technology Day 2026 at BRIC–National Institute of Immunology (NII), New…

Patient dies after oxygen supply stops in ambulance

Family stages protest outside hospital mortuary, demands action A 20-year-old patient referred from Pali to Jodhpur died in an ambulance after the oxygen supply reportedly stopped midway. Following the incident,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

ICMR transfers three Indigenous Medical Technologies to Industry at National Technology Day 2026

Will ‘Epidemic’ of Bridge Collapse in Bihar halt with new Minister in?

Will ‘Epidemic’ of Bridge Collapse in Bihar halt with new Minister in?

Patient dies after oxygen supply stops in ambulance

Patient dies after oxygen supply stops in ambulance

IndiaAI, ICMR sign MoU to advance AI in healthcare

IndiaAI, ICMR sign MoU to advance AI in healthcare

Illegal drug manufacturing racket busted in Baddi area

Illegal drug manufacturing racket busted in Baddi area

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum

US FDA and Telangana DCA bolster global pharma safety at second regulatory forum